Measuring Transparency in the Public Pharmaceutical Sector
Before, during or after procurement to identify vulnerability of the system to corruption and/or unethical practices.
- Sub-categories HIV/AIDS, Malaria, Reproductive health, TB
- Commodities Diagnostics, Medicines, Reproductive health products
- Latest update 2009
- Version None
- Developed by WHO/OMS
- When to use Before, during or after procurement to identify vulnerability of the system to corruption and/or unethical practices.
- Languages English
- Level of use Central, District, Regional
- Form PDF document, 1.4 MB - printed copies also available
- Amount of training / TA required Training: 3 days. Technical assistance: 3 days. Feedback workshop: 2.5 days
- Inputs & outputs Inputs: questionnaire forms on eight functions of the pharmaceutical system, independent national assessors, key informants. Outputs: level of transparency and vulnerability to corruption in the public pharmaceutical system, recommendations, policy guidance.
- Cost Free
- Advantages Provides evidence for advocating policy change in a sensitive area. Raises awareness of key informants and national team on forms and potential impact of corruption in their country. Provides solid basis for formulation of a national framework on good governance for medicines.
- Limitations Difficulty in identifying key informants and obtaining straightforward answers. Results may be biased if key informant selection is not appropriate (the instrument provides guidance). Assumption that greater transparency leads to less corruption.
- Availability http://www.who.int/medicines/areas/policy/goodgovernance/AssessmentInstrumentMeastranspENG.PDF
- Remarks For more information contact WHO or visit: www.who.int/medicines/ggm
- Contact email@example.com
- Submission date 2010-07-06 15:50:05